Market Overview:
The global postmenopausal osteoporosis drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of osteoporosis, rising geriatric population, and growing awareness about postmenopausal osteoporosis drugs. The global postmenopausal osteoporosis drugs market is segmented on the basis of type into antiresorptive medications and anabolic medications. The antiresorptive medications segment is further sub-segmented into bisphosphonates, denosumab, calcitonin, teriparatide, and others. The anabolic medications segment is further sub-segmented into estrogen replacement therapy (ERT), testosterone replacement therapy (TRT), selective estrogen receptor modulators (SERMs), and others. Bisphosphonates are the most commonly prescribed antiresorptive medication for treating postmenopausal osteoporosis as they are effective in reducing bone loss and fracture risk.
Product Definition:
Postmenopausal osteoporosis drugs are medications used to treat or prevent osteoporosis in postmenopausal women. These drugs work by slowing the loss of bone mineral density and may help increase bone mass.
Antiresorptive Medications:
Antiresorptive medications are the drugs that reduce or eliminate the formation of new bone tissue. They act by decreasing or blocking resorption, which is the process by which bones absorb bone tissue from around them. Osteoporosis is a disease characterized by low bone density, causing fractures even at relatively minor trauma.
Anabolic Medications:
Anabolic medications are synthetic drugs that stimulate the body to make more protein. They work by increasing the rate of protein synthesis and muscle growth, hence they are used in postmenopausal osteoporosis to increase bone density and strength of bones.
Application Insights:
The other application segment includes osteoarthritis, bone metastasis and spinal disorders. The hospital segment dominated the global market in terms of revenue in 2017. This is due to a large number of postmenopausal women patients suffering from osteoporosis who are admitted in hospitals across the world for treatment purposes. As per the U.S National Library of Medicine National Institutes of Health, around 1 out of 3 women aged between 50 to 74 years suffer from low bone mass/osteoporosis and around 2-3 out of 10 menopausal women develop osteoarthritis (OA) during their lifetime which boosts market demand globally as well as locally.
Regional Analysis:
North America dominated the global postmenopausal osteoporosis drugs market in 2017. This is attributed to the high prevalence of osteoporosis-related fractures, increasing geriatric population, and rising healthcare expenditure in this region. In addition, favorable reimbursement policies for branded medicines are also expected to drive growth during the forecast period. Asia Pacific is expected to witness lucrative growth over the forecast period owing to improving healthcare infrastructure and growing target population base.
Growth Factors:
- Increasing awareness about postmenopausal osteoporosis and its treatment options among patients and healthcare professionals.
- Growing incidence of postmenopausal osteoporosis due to changing lifestyle and dietary habits.
- Rising demand for effective and safe therapies for the treatment of postmenopausal osteoporosis.
- Availability of novel drugs for the treatment of postmenopausal osteoporosis, such as denosumab, teriparatide, abaloparatide, romosozumab etc., which are helping to drive market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Postmenopausal Osteoporosis Drugs Market Research Report
By Type
Antiresorptive Medications, Anabolic Medications
By Application
Hospital, Pharmacy, Other
By Companies
Eli Lilly, Amgen, Merck, Novartis, Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Eli Lilly, PhytoHealth, Radius Health, Tarsa Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
184
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Postmenopausal Osteoporosis Drugs Market Report Segments:
The global Postmenopausal Osteoporosis Drugs market is segmented on the basis of:
Types
Antiresorptive Medications, Anabolic Medications
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Amgen
- Merck
- Novartis
- Allergan
- Amgen Astellas Biopharm
- Deltanoid Pharmaceuticals
- Noven
- Novo Nordisk
- Osteologix
- Eli Lilly
- PhytoHealth
- Radius Health
- Tarsa Therapeutics
Highlights of The Postmenopausal Osteoporosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antiresorptive Medications
- Anabolic Medications
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Postmenopausal Osteoporosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Postmenopausal osteoporosis drugs are medications that help to prevent or treat bone loss in postmenopausal women. These drugs can be used alone or in combination with other treatments.
Some of the major players in the postmenopausal osteoporosis drugs market are Eli Lilly, Amgen, Merck, Novartis, Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Eli Lilly, PhytoHealth, Radius Health, Tarsa Therapeutics.
The postmenopausal osteoporosis drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Postmenopausal Osteoporosis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Postmenopausal Osteoporosis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Postmenopausal Osteoporosis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Postmenopausal Osteoporosis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Postmenopausal Osteoporosis Drugs Market Size & Forecast, 2018-2028
4.5.1 Postmenopausal Osteoporosis Drugs Market Size and Y-o-Y Growth
4.5.2 Postmenopausal Osteoporosis Drugs Market Absolute $ Opportunity
Chapter 5 Global Postmenopausal Osteoporosis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Postmenopausal Osteoporosis Drugs Market Size Forecast by Type
5.2.1 Antiresorptive Medications
5.2.2 Anabolic Medications
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Postmenopausal Osteoporosis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Postmenopausal Osteoporosis Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Postmenopausal Osteoporosis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Postmenopausal Osteoporosis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Postmenopausal Osteoporosis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Postmenopausal Osteoporosis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Postmenopausal Osteoporosis Drugs Market Size Forecast by Type
9.6.1 Antiresorptive Medications
9.6.2 Anabolic Medications
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Postmenopausal Osteoporosis Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Postmenopausal Osteoporosis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Postmenopausal Osteoporosis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Postmenopausal Osteoporosis Drugs Market Size Forecast by Type
10.6.1 Antiresorptive Medications
10.6.2 Anabolic Medications
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Postmenopausal Osteoporosis Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Postmenopausal Osteoporosis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Postmenopausal Osteoporosis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Postmenopausal Osteoporosis Drugs Market Size Forecast by Type
11.6.1 Antiresorptive Medications
11.6.2 Anabolic Medications
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Postmenopausal Osteoporosis Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Postmenopausal Osteoporosis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Postmenopausal Osteoporosis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Postmenopausal Osteoporosis Drugs Market Size Forecast by Type
12.6.1 Antiresorptive Medications
12.6.2 Anabolic Medications
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Postmenopausal Osteoporosis Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Postmenopausal Osteoporosis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Postmenopausal Osteoporosis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Postmenopausal Osteoporosis Drugs Market Size Forecast by Type
13.6.1 Antiresorptive Medications
13.6.2 Anabolic Medications
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Postmenopausal Osteoporosis Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Postmenopausal Osteoporosis Drugs Market: Competitive Dashboard
14.2 Global Postmenopausal Osteoporosis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Amgen
14.3.3 Merck
14.3.4 Novartis
14.3.5 Allergan
14.3.6 Amgen Astellas Biopharm
14.3.7 Deltanoid Pharmaceuticals
14.3.8 Noven
14.3.9 Novo Nordisk
14.3.10 Osteologix
14.3.11 Eli Lilly
14.3.12 PhytoHealth
14.3.13 Radius Health
14.3.14 Tarsa Therapeutics
